menu
    • menu
    [{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Etelcalcetide","moa":"CaSR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alphadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ono Pharmaceutical \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ SK Biopharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Ono Pharmaceutical

    Menu

    Ono Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : Vertex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ono and Vertex To Develop and Launch Povetacicept in Japan and South Korea

                            Details : Under the licensing agreement, Ono will utilize its expertise to help advance Vertex’s trials for ALPN-303 (povetacicept) and will be obtaining marketing authorizations in Japan and South Korea.

                            Product Name : ALPN-303

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 23, 2025

                            Lead Product(s) : Povetacicept

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : Vertex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cenobamate Demonstrates Clinical Efficacy and Safety across Korea, China and Japan

                            Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.

                            Product Name : Xcopri

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Cenobamate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirabrutinib Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO PHARMA Completes Enrollment for PROSPECT Study On Tirabrutinib

                            Details : ONO-4059 (tirabrutinib) is a highly selective irreversible Bruton's tyrosine kinase inhibitor. It is being evaluated for patients with relapsed or refractory primary central nervous system lymphoma.

                            Product Name : Velexbru

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : Tirabrutinib Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirabrutinib Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO PHARMA USA's Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Centr...

                            Details : Velexbru (tirabrutinib hydrochloride) is a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor. It has received orphan drug designation from the FDA for the treatment of primary central nervous system lymphoma.

                            Product Name : Velexbru

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2023

                            Lead Product(s) : Tirabrutinib Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opdivo® Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in C...

                            Details : Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. It is been approved for treating resectable non-small cell lung cancer in Taiwan.

                            Product Name : Opdivo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 24, 2023

                            Lead Product(s) : Nivolumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BRAFTOVI® Capsule, a BRAF Inhibitor, Approved in South Korea for Treatment of Advanced or Recurrent BRAFV600E...

                            Details : In this study, BRAFTOVI and cetuximab combination treatment group demonstrated a statistically significant extension in overall survival (OS), versus the control group (irinotecan and cetuximab based combination treatment).

                            Product Name : Braftovi

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 20, 2021

                            Lead Product(s) : Encorafenib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opdivo and Yervoy Combination Therapy Approved in Japan for First-line Treatment of Unresectable Malignant Ple...

                            Details : Opdivo®, a human PD-1 monoclonal antibody, and Yervoy® Injection, a human monoclonal antibody against CTLA-4, in combination therapy for the first-line treatment of unresectable advanced or recurrent malignant pleural mesothelioma.

                            Product Name : Opdivo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 27, 2021

                            Lead Product(s) : Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Cancer of Unk...

                            Details : This application is based on the result from an investigator-initiated clinical study (NivoCUP study), conducted under the initiative of Kindai University Hospital, evaluating Opdivo in patients with cancer of unknown primary (CUP).

                            Product Name : Opdivo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anamorelin HCl

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ONO Receives a Manufacturing and Marketing Approval of Adlumiz®, a Ghrelin Receptor Agonist for the Treatment...

                            Details : Marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”) is mainly based on the results from the ONO-7643-04 and ONO-7643-05 studies conducted in Japan in patients with cancer cachexia.

                            Product Name : Adlumiz

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : Anamorelin HCl

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ono Pharmaceutical

                            Japan arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etelcalcetide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Parsabiv IV Injection Syringe Launched in Japan for Dialysis Patients

                            Details : Parsabiv (etelcalcetide HCl) is a calcium-sensing receptor agonist indicated for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

                            Product Name : Parsabiv

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : Etelcalcetide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth